Studies

Showing 11 studies.

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

Research Area

Study Status

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

Research Area

Study Status

IMPAACT 2017: MOCHA

DAIDS Number

Research Area

Study Status

Closed to Accrual

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

Research Area

Study Status

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

Research Area

Study Status

P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT

DAIDS Number

Research Area

Mother to child transmission

Study Status

Temporarily Closed (Paused) to Accrual and Study Agents/Products

P1080: ARV & Psychiatric Medication Concentrations in HIV Infected & Uninfected Children

DAIDS Number

Research Area

Brain and Mental Health

Study Status

Closed to Follow Up

P1063: Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of Increased LDL-Cholesterol in HIV-Infected children, Adolescents, and Young Adults

DAIDS Number

Research Area

Complications & Comorbidities

Study Status